title: Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus.
abstract: Refractory status epilepticus (RSE) and superrefractory status epilepticus (SRSE) pose a difficult clinical challenge. Multiple cerebral receptor and transporter changes occur with prolonged status epilepticus leading to pharmacoresistance patterns unfavorable for conventional antiepileptics. In particular, n-methyl-d-aspartate (NMDA) receptor upregulation leads to glutamate mediated excitotoxicity. Targeting these NMDA receptors may provide a novel approach to otherwise refractory seizures. Ketamine has been utilized in RSE. Recent systematic review indicates 56.5% and 63.5% cessation in seizures in adults and pediatrics, respectively. No complications were described. We should consider earlier implementation of ketamine or other NMDA receptor antagonists, for RSE. Prospective study of early implementation of ketamine should shed light on the role of such medications in RSE.
authors: Section of Neurosurgery, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada R3A 1R9.
authors: F A
authors: FA
authors: Zeiler
references: Epilepsia. 2012 Dec;53 Suppl 9:79-88
references: 23216581
references: BMJ. 2014 Feb 28;348:g254
references: 24583319
references: Neurosci Lett. 2006 Nov 13;408(2):79-83
references: 17011125
references: Epilepsia. 2008 Dec;49 Suppl 9:63-73
references: 19087119
references: Neurosci Lett. 2007 Jun 4;419(3):253-7
references: 17499921
references: Epilepsia. 2007;48 Suppl 8:74-7
references: 18330007
references: Exp Neurol. 1993 Oct;123(2):204-15
references: 8405286
references: Neuroscience. 2003;118(3):727-40
references: 12710980
references: Epilepsia. 2008 Feb;49(2):248-55
references: 17941842
references: Can J Neurol Sci. 2012 Mar;39(2):157-69
references: 22343147
references: J Crit Care. 2014 Dec;29(6):1096-106
references: 24996763
references: Epilepsia. 1995 Feb;36(2):186-95
references: 7821277
references: J Neurophysiol. 2008 Mar;99(3):1285-93
references: 18216225
references: Arch Neurol. 2002 Feb;59(2):205-10
references: 11843690
references: JAMA Neurol. 2013 Jan;70(1):72-7
references: 23318514
references: Brain. 2012 Aug;135(Pt 8):2314-28
references: 22577217
references: Neurol Res. 2013 Mar;35(2):163-8
references: 23336320
references: Brain Res. 2012 Sep 20;1474:110-7
references: 22885341
references: J Neurotrauma. 1999 Sep;16(9):843-50
references: 10521143
references: J Neurotrauma. 2005 Dec;22(12):1428-43
references: 16379581
references: CNS Neurosci Ther. 2013 Jun;19(6):411-27
references: 23601960
references: Nat Rev Neurosci. 2005 Aug;6(8):591-602
references: 16025095
references: Brain. 2011 Oct;134(Pt 10):2802-18
references: 21914716
references: Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2508-13
references: 10051673
references: Neurocrit Care. 2014 Aug;21(1):163-73
references: 24515638
references: Neurocrit Care. 2014 Jun;20(3):502-13
references: 24519081
references: Toxicology. 2007 May 20;234(3):185-93
references: 17408839
references: Epilepsy Behav. 2005 Dec;7 Suppl 3:S3-11
references: 16278099
references: Neurocrit Care. 2012 Aug;17(1):3-23
references: 22528274
references: Epilepsia. 2005 Nov;46(11):1724-43
references: 16302852